Background: There is growing interest in the immune-stimulating effect and in particular, the anti-allergic effect, of lactic acid bacteria (LAB). However, no comprehensive studies have been done that compare the immune-stimulating potential of LAB strains. Methods: The in vitro immune-stimulating effects on Th1/Th2 balance of more than 100 LAB strains were compared in splenocytes from ovalbumin-sensitized Th2-polarized mice. The in vivoanti-allergic ability of strain KW3110 was studied in the Th2-polarized model by detecting serum IgE concentration, Th1/Th2 cytokine secretion from splenocytes, and the expression of co-stimulatory molecules on macrophages. Results: In vitro studies from Th2-polarized splenocytes, using IL-12 as a Th1 parameter and IL-4 secretion as a Th2 parameter revealed a wide variety of IL-12-inducing and IL-4-repressing activities, depending on the strain of LAB, not depending on the species. However, evaluation of individual strains in vivo revealed that after exposure to Lactobacillus paracasei KW3110 strain, the serum IgE elevation elicited by repeated OVA injection of mice was strongly inhibited. Cytokine secretion from splenocytes 20 weeks after KW3110 administration showed increased IL-12 and decreased IL-4 expression. Both CD40 and B7-1 expression on macrophages was upregulated by administration of KW3110. Conclusions: Improving the consequences of the Th1/Th2 imbalance by administration of LAB was dependent upon the LAB strain rather than the LAB species. Oral KW3110 administration in the mouse allergy model directed the Th1/Th2 balance toward Th1 through the maturation of APCs and inhibition of serum IgE elevation.

Keywords:
Lactic acid bacteria, IgE, Th1, Th2, Lactobacillus paracasei strain KW3110
1.
Platts-Mills TA: The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 2001;164:1–5.
2.
Pene J, Rousset F, Briere F, Chretien I, Bonnefoy JY, Spits H: IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons γ and α and prostaglandin E2. Proc Natl Acad Sci USA 1998;85:6880–6884.
3.
Macatonia SE, Hsieh CS, Murphy KM, O’Garra A: Dendritic cells and macrophages are required for Th1 development of CD4+ T cells from ααβ TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFN-γ production is IFN-γ dependent. Int Immunol 1993;5:1119–1128.
4.
Strachan DP: Hay fever, hygiene, and household size. BMJ 1989;299:1259–1260.
5.
Ahrne S, Nobaek S, Jeppsson B, Adlerberth, Wold AE, Molin G: The normal Lactobacillus flora of healthy human rectal and oral mucosa. J Appl Microbiol 1998;85:88.
6.
Shahari KM, Friend BA, Bailey PJ: Antitumor activity of fermented colostrums and milk. J Food Product 1983;46:385–386.
7.
Pereyra BS, Lemonnier D: Induction of human cytokines by bacteria used in dairy foods. Nutr Res 1993;13:1127–1240.
8.
Takagi A, Matsuzaki T, Sato M, Nomoto K, Morotomi M, Yokokura T: Enhancement of natural killer cytotoxicity delayed murine carcinogenesis by a probiotic microorganism. Carcinogenesis 2001;22:599–605.
9.
Hatcher GE, Lambrecht RS: Augmentation of macrophage phagocytic activity by cell-free extracts of selected lactic acid-producing bacteria. J Dairy Sci 1993;76:2485–2492.
10.
Kato I, Tanaka K, Yokokura T: Lactic acid bacterium potently induces the production of interleukin-12 and interferon-γ by mouse splenocytes. Int J Immunopharmacol 1999;21:121–131.
11.
Christensen HR, Frokiaer H, Pestka JJ: Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol 2002;168:171–178.
12.
Maassen CB, van Holten-Neelen C, Balk F, den Bak-Glashouwer MJ, Leer RJ, Laman JD, Boersma WJ, Claassen E: Strain-dependent induction of cytokine profiles in the gut by orally administered Lactobacillus strains. Vaccine 2000;18:2613–2623.
13.
Haller D, Bode C, Hammes WP, Pfeifer AMA, Schiffrin EJ, Blum S: Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut 2000;47:79–87.
14.
Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ: Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem 1999;274:17406–17409.
15.
Schröder NWJ, Morath S, Alexander C, Hamann L, Hartung T, Zähringer U, Göbel UB, Weber J, Schuman RR: Lipoteichoic Acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J Biol Chem 2003;278:15587–15594.
16.
Fujimoto T, Duda RB, Szilvasi A, Chen X, Mai M, O’Donnell MA: Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state. J Immunol 1997;158:5619–5626.
17.
Selden RF: Transfection using DEAE-dextran; In Short Protocols in Molecular Biology, ed 3. New York, Wiley, 1995;9-9-9-11.
18.
Nagura T, Hachimura S, Hashiguchi M, Ueda Y, Kanno T, Kikuchi H, Sayama K, Kaminogawa S: Suppressive effect of dietary raffinose on T-helper 2 cell-mediated immunity. Br J Nutr 2002;88:421–426.
19.
Morath S, Geyer A, Hartung T: Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus. J Exp Med 2001;193:393–397.
20.
Veckman V, Miettinen M, Matikainen S, Lande R, Giacomini E, Coccia EM, Julkunen I: Lactobacilli and streptococci induce inflammatory chemokine production in human macrophages that stimulates Th1 cell chemotaxis. J Leukoc Biol 2003;74:395–402.
21.
Murphy TL, Cleveland MG, Kulesza P, Magram J, Murphy KM: Regulation of interleukin 12 p40 expression through an NF-kappa B half- site. Mol Cell Biol 1995;15:5258–5267.
22.
Ginsburg I: Role of lipoteichoic acid in infection and inflammation. Lancet Infect Dis. 2002;2:171–179.
23.
Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira S: Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999;11:443–451.
24.
Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G: Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996;184:747–752.
25.
McDyer JF, Goletz TJ, Thomas E, June CH, Seder RA: CD40 ligand/CD40 stimulation regulates the production of IFN-gamma from human peripheral blood mononuclear cells in an IL-12- and/or CD28-dependent manner. J Immunol 1998;160:1701–1707.
26.
Chiaramonte MG, Hesse M, Cheever AW, Wynn TA: CpG oligonucleotides can prophylactically immunize against Th2-mediated schistosome egg-induced pathology by an IL-12-independent mechanism. J Immunol 2000;164:973–985.
27.
Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM: CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 1996;93:2879–2883.
28.
Gupta D, Wang Q, Vinson C, Dziarski R: Bacterial peptidoglycan induces CD14-dependent activation of transcription factors CREB/ATF and AP-1. J Biol Chem 1999;274:14012–14020.
29.
Bhakdi S, Klonisch T, Nuber P, Fischer W: Stimulation of monokine production by lipoteichoic acids. Infect Immun 1991;59:4614–4620.
30.
Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765.
31.
Rescigno M, Urbano M, Valzasina B, Francolini M, Rotta G, Bonasio R, Granucci F, Kraehenbuhl JP, Ricciardi-Castagnoli P: Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol. 2001;2:361–367.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.